Incyte Approval In Subset Of Cholangiocarcinoma May Lead To Bigger Opportunities

 
• By Joseph Haas

Biotech hopes this initial approval will be followed by approvals of Pemazyre in bladder cancer, first-line cholangiocarcinoma and possibly even a tumor-agnostic indication for FGFR-mutated cancers.

Desk_Hand
Incyte got FDA's thumbs-up for Pemazyre in cholangiocarcinoma

More from New Products

More from Scrip